For the nearly 185,000 Americans who suffer a recurrent stroke each year, new research presented at the American Heart Association's Scientific Sessions 2026 offers a clear, evidence-based path to reducing that risk. The OPTIMAL-Stroke trial, conducted across 30 health centers in Brazil, found that intensively lowering systolic blood pressure to less than 120 mm Hg in survivors of an ischemic stroke or transient ischemic attack (TIA) significantly reduced the risk of future strokes, heart attacks, and other major cardiovascular events compared with the standard target of less than 140 mm Hg.
The study's implications are substantial. Over an average follow-up of 3.9 years, participants in the intensive treatment group were about 21% less likely to experience a major cardiovascular event—10.9% versus 13.5% in the standard treatment group. Recurrent strokes occurred in 4.7% of the intensive group versus 6.4% of the standard group, driven primarily by fewer ischemic strokes. These findings, simultaneously published in the New England Journal of Medicine, challenge conventional wisdom and suggest that more aggressive blood pressure management could become a cornerstone of secondary stroke prevention.
High blood pressure is the single most important modifiable risk factor for stroke. Current guidelines, such as the Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack, emphasize controlling risk factors to prevent recurrent events. The 2025 Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults recommends maintaining systolic blood pressure under 130 mm Hg and encourages values below 120 mm Hg for people at increased cardiovascular risk. The OPTIMAL-Stroke trial provides robust evidence supporting these more ambitious targets for stroke survivors.
However, the trial also underscores the need for caution. While serious adverse events were similar between groups, kidney-related events increased in the intensive treatment group, highlighting the importance of individualized treatment and careful monitoring of kidney function. "Achieving lower blood pressure safely requires appropriate medical supervision and additional monitoring," said principal investigator Gisele Sampaio, M.D., Ph.D. The study's limitation—that not all participants achieved the target below 120 mm Hg—suggests that real-world implementation will require tailored approaches.
For patients and clinicians, the message is clear: know your blood pressure, take prescribed medications consistently, and discuss individual targets with your healthcare team. As Sampaio noted, "A lower blood pressure target may offer greater protection, and we must ensure that the right target is achieved safely and tailored to each patient." Resources such as Preventing Another Stroke and Understanding Blood Pressure Readings can help patients navigate this new paradigm. The findings will be presented at Scientific Sessions 2026, a premier global exchange of cardiovascular science.
